JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.3
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 14, Issue 2 (2022)
Iran J War Public Health 2022, 14(2): 133-138 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2021/12/11 | Accepted: 2022/04/14 | Published: 2022/05/21
Received: 2021/12/11 | Accepted: 2022/04/14 | Published: 2022/05/21
How to cite this article
Abdulhussein S, Al-Kazazz F, Rheima A. The Risk Factors in Serum of Peripheral Neuropathy Diabetic and Type 2 Diabetes Patients. Iran J War Public Health 2022; 14 (2) :133-138
URL: http://ijwph.ir/article-1-1076-en.html
URL: http://ijwph.ir/article-1-1076-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Chemistry, College of Science, Mustansiriyah University, Baghdad, Iraq
Abstract (947 Views)
Aims: The study's purpose was to evaluate the serious risk factor for the neuropathy disease in patients with diabetes
Material & Methods: This research was done on 120 subjects classified into 40 with DPN T2DM and 40 with T2DM and 40 healthy considered as a control. As the conditions of the Iraqi Ministry of Health to evaluate the thesis clinically, that the number of samples examined should be at least 120 samples. The collection period was from 1 October 2021 to 1 December 2021. All patients and control groups were collected from medical City Al-Imamian, Al-Kadhmiyain-Baghdad-Iraq. Regression analysis was used to investigate potential risky factorize lead for the DPN in T2DM patients.
Findings: The spread of DPN in Type 2 diabetic patients was 50% of the multiple logistic transformations revealed in diabetic peripheral neuropathy. The mean value of Duration was significant (p<0.05) for DPN compared with T2DM. The mean value of fasting glucose, HbA1c, and hypertension, for DPN participants, were significantly higher than in T2DM and control groups (p=0.0001). The analysis of variance for vitamin B12 and vitamin D was significant (p=0.0001) for DPN it was lower than for T2DM and control. The mean value of lipid profile was non-significant (p>0.05) between the three groups.
Conclusion: Diabetic peripheral neuropathy had a high risk of a decrease in their vitamin B12 and vitamin D levels. On another hand, patients with T2DM should follow up on their vitamin levels periodically.
Material & Methods: This research was done on 120 subjects classified into 40 with DPN T2DM and 40 with T2DM and 40 healthy considered as a control. As the conditions of the Iraqi Ministry of Health to evaluate the thesis clinically, that the number of samples examined should be at least 120 samples. The collection period was from 1 October 2021 to 1 December 2021. All patients and control groups were collected from medical City Al-Imamian, Al-Kadhmiyain-Baghdad-Iraq. Regression analysis was used to investigate potential risky factorize lead for the DPN in T2DM patients.
Findings: The spread of DPN in Type 2 diabetic patients was 50% of the multiple logistic transformations revealed in diabetic peripheral neuropathy. The mean value of Duration was significant (p<0.05) for DPN compared with T2DM. The mean value of fasting glucose, HbA1c, and hypertension, for DPN participants, were significantly higher than in T2DM and control groups (p=0.0001). The analysis of variance for vitamin B12 and vitamin D was significant (p=0.0001) for DPN it was lower than for T2DM and control. The mean value of lipid profile was non-significant (p>0.05) between the three groups.
Conclusion: Diabetic peripheral neuropathy had a high risk of a decrease in their vitamin B12 and vitamin D levels. On another hand, patients with T2DM should follow up on their vitamin levels periodically.
Keywords:
References
1. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort: the rochester diabetic neuropathy study. Neurology. 1993;43(4):817. [Link] [DOI:10.1212/WNL.43.4.817]
2. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473. [Link] [DOI:10.1007/s11910-014-0473-5]
3. Dietrich I, Braga GA, de Melo FG, da Costa Silva ACC. The diabetic foot as a proxy for cardiovascular events and mortality review. Curr Atherosclerosis Rep. 2017;19(11):1-5. [Link] [DOI:10.1007/s11883-017-0680-z]
4. Tura A, Chemello G, Szendroedi J, Goebl C, Faerch K, Vrbikova J, et al. Prediction of clamp-derived insulin sensitivity from the oral glucose insulin sensitivity index. Diabetologia. 2018;61(5):1135-41. [Link] [DOI:10.1007/s00125-018-4568-4]
5. L'Heveder R, Nolan T. International diabetes federation. Diabetes Res Clin Pract. 2013;101(3):349-51. [Link] [DOI:10.1016/j.diabres.2013.08.003]
6. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367-75. [Link] [DOI:10.1056/NEJMra1615439]
7. Callaghan BC, Gao L, Li Y, Zhou X, Reynolds E, Banerjee M, et al. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clin Translat Neurol. 2018;5(4):397-405. [Link] [DOI:10.1002/acn3.531]
8. Sadosky A, Mardekian J, Parsons B, Hopps M, Bienen EJ, Markman J. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015;29(2):212-7. [Link] [DOI:10.1016/j.jdiacomp.2014.10.013]
9. Kioskli K, Scott W, Winkley K, Kylakos S, McCracken LM. Psychosocial factors in painful diabetic neuropathy: a systematic review of treatment trials and survey studies. Pain Med. 2019;20(9):1756-73. [Link] [DOI:10.1093/pm/pnz071]
10. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-54. [Link] [DOI:10.2337/dc16-2042]
11. Walton DM, Minton SD, Cook AD. The potential of transdermal nitric oxide treatment for diabetic peripheral neuropathy and diabetic foot ulcers. Diabetes Metab Syndr. 2019;13(5):3053-6. [Link] [DOI:10.1016/j.dsx.2018.07.003]
12. Yang H, Sloan G, Ye Y, Wang S, Duan B, Tesfaye S, Gao L. New perspective in diabetic neuropathy: from the periphery to the brain, a call for early detection, and precision medicine. Front Endocrinol. 2020;10:929. [Link] [DOI:10.3389/fendo.2019.00929]
13. Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: risk factors, diagnosis and treatment. World J Diabetes. 2018;9(1):1-24. [Link] [DOI:10.4239/wjd.v9.i1.1]
14. Roglic G, editor. Global report on diabetes. Geneva: World Health Organization; 2016 [Link] [DOI:10.4103/2468-8827.184853]
15. Barrett EJ, Liu Z, Khamaisi M, King GL, Klein R, Klein BE, et al. Diabetic microvascular disease: an endocrine society scientific statement. J Clin Endocrinol Metab. 2017;102(12):4343-410. [Link] [DOI:10.1210/jc.2017-01922]
16. Javed S, Hayat T, Menon L, Alam U, Malik RA. Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late. Diabetic Med. 2020;37(4):573-9. [Link] [DOI:10.1111/dme.14194]
17. Karthik L, Kumar G, Keswani T, Bhattacharyya A, Chandar SS, Bhaskara Rao KV. Protease inhibitors from marine actinobacteria as a potential source for antimalarial compound. PloS One. 2014;9(3):e90972. [Link] [DOI:10.1371/journal.pone.0090972]
18. Wysocka-Mincewicz M, Baszyńska-Wilk M, Mazur M, Byczyńska A, Nowacka-Gotowiec M. Thyroid hormones, peripheral white blood count, and dose of basal insulin are associated with changes in nerve conduction studies in adolescents with type 1 diabetes. Metabolites. 2021;11(11):795. [Link] [DOI:10.3390/metabo11110795]
19. Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994;60(1):2-11. [Link] [DOI:10.1093/ajcn/60.1.2]
20. Assy MH, Draz NA, Fathy SE, Hamed MG. Impact of vitamin D level in diabetic people with peripheral neuropathy. Egyp J Neurol Psychiatry Neurosurgery. 2021;57(1):1-7. [Link] [DOI:10.1186/s41983-021-00370-9]
21. Barlow SE, Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120 Suppl 4:S164-92. [Link] [DOI:10.1542/peds.2007-2329C]
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. [Link] [DOI:10.1093/clinchem/18.6.499]
23. Dhumad MM, Hamdan FB, Khudhair MS, Al-Matubsi HY. Correlation of staging and risk factors with cardiovascular autonomic neuropathy in patients with type II diabetes mellitus. Sci Rep. 2021;11(1):3576. [Link] [DOI:10.1038/s41598-021-80962-w]
24. Wang F, Zheng M, Hu J, Fang C, Chen T, Wang M, et al. Value of shear wave elastography combined with the Toronto clinical scoring system in diagnosis of diabetic peripheral neuropathy. Medicine. 2021;100(35):e27104. [Link] [DOI:10.1097/MD.0000000000027104]
25. Huang L, Shen X, Huang L, Yan S, Wu P. Identification of independent risk factors for diabetic neuropathy progression in patients with type 2 diabetes mellitus. J Int Med Res. 2021;49(9):03000605211044366. [Link] [DOI:10.1177/03000605211044366]
26. Abdel-Rahman T, Helaly MA, El-Arman M, El-Ghany A, Ibrahim,M. Characteristics of type 2 diabetes mellitus in Egyptian elderly population. Mansoura Med J. 2021;50(3):93-105. [Link] [DOI:10.21608/mjmu.2021.93162.1037]
27. Ali HAEM, Al Adl AS. Study the role of dyslipidemia in cases of neuropathy with type 2 diabetes mellitus. Al-Azhar Assiut Med J. 2021;19(1):143. [Link]
28. AL-Khateeb ZM, Abdulsattar SA, Salman APDIN. Assessment of serum high mobility group Box-1 level as predictor of diabetic peripheral neuropathy. J Hunan Univ Nat Sci. 2021;48(9):348-57. [Link]
29. Zhu T, Meng Q, Ji J, Lou X, Zhang L. Toll-like receptor 4 and tumor necrosis factor-alpha as diagnostic biomarkers for diabetic peripheral neuropathy. Neurosci Lett. 2015;585:28-32. [Link] [DOI:10.1016/j.neulet.2014.11.020]
30. Atabi DF, Qasim AH, Mohammed SAK, Al-Saadawi AIO. Association of metformin use with vitamin B12 deficiency in iraqi patients with type ii diabetes mellitus. Indian J Forensic Med Toxicol. 2021;15(3):4729. [Link]
31. Kwape L, Ocampo C, Oyekunle A, Mwita JC. Vitamin B12 deficiency in patients with diabetes at a specialised diabetes clinic, Botswana. J Endocrinol Metab Diabetes South Afr. 2021;26(3):101-5. [Link] [DOI:10.1080/16089677.2021.1927586]
32. Hamdi RA. A review on vitamin B12 and diabetic neuropathy. Iraqi postgraduate medical J. 2021;20(2). [Link]
33. Hong SH, Kim YB, Choi HS, Jeong TD, Kim JT, Sung YA. Association of vitamin D deficiency with diabetic nephropathy. Endocrinol Metab. 2021;36(1):106-13. [Link] [DOI:10.3803/EnM.2020.826]
34. Fithrie A, Fitri FI, Putra MR. Association of vitamin D level and nerve conduction study parameters with cognitive function in diabetic neuropathy patients. Open Access Macedonian J Med Sci. 2021;9(B):72-8. [Link] [DOI:10.3889/oamjms.2021.5938]
35. Butler AE, Dargham SR, Latif A, Mokhtar HR, Robay A, Chidiac OM, et al. Association of vitamin D3 and its metabolites in patients with and without type 2 diabetes and their relationship to diabetes complications. Ther Adv Chronic Dis. 2020;11:2040622320924159. [Link] [DOI:10.1177/2040622320924159]
36. Zhao WJ, Xia XY, Yin J. Relationship of serum vitamin D levels with diabetic microvascular complications in patients with type 2 diabetes mellitus. Chin Med J. 2021;134(7):814-20. [Link] [DOI:10.1097/CM9.0000000000001364]
37. Oh TJ, Lee JE, Choi SH, Jang HC. Association between body fat and diabetic peripheral neuropathy in middle-aged adults with type 2 diabetes mellitus: a preliminary report. J Ob Metab Syndr. 2019;28(2):112-7. [Link] [DOI:10.7570/jomes.2019.28.2.112]
38. Mussa BM, Srivastava A, Al-Habshi A, Mohammed AK, Halwani R, Abusnana S. Inflammatory biomarkers levels in T2DM Emirati patients with diabetic neuropathy. Diabetes Metab Syndr Obes. 2021;14:3389-97. [Link] [DOI:10.2147/DMSO.S319863]
39. Zhuang Y, Lin X, Chen X, Wu X, Zhang J. Fibrinogen function indexes, potential biomarkers, are closely connected to diabetic peripheral neuropathy. Diabetes Metab Syndr. 2021;14:13. [Link] [DOI:10.1186/s13098-021-00777-7]
40. Hu Y, Yan Z, Pan C. Associations of thyroid hormone levels and macrovascular complications in euthyroid type 2 diabetic patients. Diabet Metab Syndr Obes. 2021; 14: 2683-91. [Link] [DOI:10.2147/DMSO.S313803]
41. Mohapatra D, Sampath Damodar K. Glycaemia status, lipid profile and renal parameters in progressive diabetic neuropathy. J Clin Diagn Res. 2016;10(9):CC14-7. [Link] [DOI:10.7860/JCDR/2016/20004.8515]
42. Buraczynska M, Buraczynska K, Dragan M, Ksiazek A. Pro198 Leu 2017 polymorphism in the glutathione peroxidase 1 gene contributes to diabetic peripheral neuropathy in type 2 diabetes patients. Neuromolecular Med. 19(1):147-53. [Link] [DOI:10.1007/s12017-016-8438-2]
43. Cai Z, Yang Y, Zhang J. A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy. Sci Rep. 2021;11:499. [Link] [DOI:10.1038/s41598-020-79276-0]